RL66 a second-generation curcumin analog has potent in vivo and in vitro anticancer activity in ER-negative breast cancer models

BABASAHEB YADAV1, SEBSTIEN TAURIN1, LESLEY LARSEN2 and RHONDA J. ROSENGREN1

Departments of 1Pharmacology and Toxicology, 2Chemistry, University of Otago, Dunedin, New Zealand

Received June 3, 2012; Accepted July 30, 2012

DOI: 10.3892/ijo.2012.1625

Abstract. There is a need for the development of new safe and efficacious drug therapies for the treatment of estrogen receptor (ER)-negative breast cancers. 1-Methyl-3,5-bis[(E)-4-pyridyl)methylidene]-4-piperidone (RL66) is a second generation curcumin analog that exhibits potent cytotoxicity towards a variety of ER-negative breast cancer cells. Therefore, we have further examined the mechanism of this novel drug in vitro and in vivo models of ER-negative breast cancer. The mechanistic studies demonstrated that RL66 (2 μM) induced cell cycle arrest in the G2/M phase of the cell cycle. Moreover, RL66 (2 μM) caused 40% of SKBr3 cells to undergo apoptosis after 48 h and this effect was time-dependent. This correlated with an increase in cleaved caspase-3 as shown by western blot analysis. RL66 (2 μM) also decreased HER2/neu phosphorylation and increased p27 in SKBr3 cells, while in MDA-MB-231 and MDA-MB-468 cells RL66 (2 μM) significantly decreased Akt phosphorylation and transiently increased the stress kinases JNK1/2 and MAPK p38. In addition, RL66 exhibited anti-angiogenic potential in vitro as it inhibited HUVEC cell migration 46% and the ability of these cells to form tube-like networks. RL66 (8.5 mg/kg) suppressed the growth of MDA-MB-468 xenograft tumors by 48% compared to vehicle control following 10 weeks of daily oral administration. Microvessel density in the tumors from treated mice was also decreased 57% compared to control. Thus our findings demonstrate that RL66 has potent proapoptotic and anti-angiogenic properties in vivo and in vitro and has the potential to be further developed as a drug for the treatment of ER-negative breast cancer.

Introduction

Breast cancer is the most prevalent form of cancer diagnosed in women, and there continues to be limited drug treatment options for the ~30% of patients with estrogen receptor (ER)-negative breast cancer (1,2). In the search for effective drugs for ER-negative breast cancer, several lead compounds from natural products have emerged including curcumin (diferuloylmethane), the primary bioactive compound isolated from the rhizome of turmeric (Curcuma longa Linn.). Curcumin has numerous pharmacological, chemopreventative and chemotherapeutic actions, and in vitro studies have also demonstrated that curcumin exhibits potent cytotoxicity toward numerous cell lines including ER-negative human breast cancer cells (3-9). Furthermore, in vivo studies have demonstrated decreased tumorigenesis of many organs, including the mammary gland (10-15). However, curcumin has shown limited clinical efficacy, due to its low bioavailability and low stability (11). Therefore, numerous groups have concentrated on improving drug efficacy, bioavailability and stability by synthesizing analogs of curcumin. Specifically, cyclohexanone analogs of curcumin have shown enhanced activity and stability compared to curcumin (16). Specifically, the cyclohexanone-containing curcumin derivative 2,6-bis(3-methoxy-4-hydroxyphenyl)methylene)cyclohexanone (BMHPC) was cytotoxic towards ER-negative breast cancer cells (IC50 of 5.0 μM) (17), although bioavailability and in vivo efficacy were still problematic. More recently the fluorinated cyclohexanone derivative EF24 has shown potent cytotoxicity toward MDA-MB-231 cells with an IC50 value of 0.8 μM (18,19).

Our laboratory has been involved in the search for new drug treatments for ER-negative breast cancer and we have shown that 2nd generation heterocyclic cyclohexanone curcumin analogs exhibit potent cytotoxicity toward ER-negative breast cancer cells. This work demonstrated that 1-methyl-3,5-bis[(E)-4-pyridyl)methylidene]-4-piperidone (RL66) (Fig. 1) exhibited IC50 values of 0.8, 0.5 and 0.6 μM for MDA-MB-231, MDA-MB-468 and SKBr3 breast cancer cells, respectively (20). It also induced apoptosis, as ~18% of MDA-MB-231 cells underwent apoptosis after 12 h of RL66 treatment (2 μM) (20). Only one other compound synthesized (RL71) showed a more potent effect in vitro (21), but this compound did not suppress tumor growth in vivo. Therefore, this study was designed to comprehensively investigate the potency and mechanisms of action of RL66 in vitro and in vivo in order to determine its potential to be developed into a drug for ER-negative breast cancer.
Materials and methods

Materials. HUVEC, MDA-MB-231, MDA-MB-468 and SKBr3 cells were purchased from American Type Culture Collection (Manassas, VA, USA). Primary antibodies to NF-κB, p38, pp38, NF-κB, JNK, pJNK, cleaved caspase-3, 4EBP1, p4EBP1, p27, mTOR, pmTOR, HER2, pHER2 and β-actin were purchased from Cell Signaling Technology (Danvers, MA, USA). Akt and pAkt primary antibodies were purchased from BD Biosciences (Auckland, New Zealand). Dulbecco’s modified Eagle’s medium (DMEM) nutrient mixture Ham’s F-12, sulfonhodamine B salt, propidium iodide (PI), ammonium persulfate, horseradish peroxidase were purchased from Sigma-Aldrich (Auckland, New Zealand). Acrylamide, bisacrylamide, sodium dodecylsulfate and PVDF membrane were purchased from Bio-Rad Laboratories (Hercules, CA, USA). Complete mini EDTA-free protease inhibitor cocktail and Annexin V-FLUOS were purchased from Roche Diagnostics Corporation (Mannheim, Germany). RL66 was prepared as described previously (18). All other chemicals were of the highest purity commercially available.

Cell maintenance. MDA-MB-231, MDA-MB-468 and SKBr3 cells were maintained in complete growth media composed of DMEM/Ham’s F12 supplemented with 5% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml streptomycin, 250 ng/ml amphotericin B, and 100 U/ml penicillin and 2.2 g/l NaHCO₃.

Cytotoxicity. MDA-MB-231, MDA-MB-468 and SKBr3 cells (95x10⁴ cells/well) were seeded in 12-well plates in 1 ml DMEM/Ham’s F12 supplemented with 5% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, 25 ng/ml amphotericin B and 2.2 g/l NaHCO₃ and incubated for 24 h at 37°C. To determine cytotoxicity over a time-course, cells were treated with RL66 (1.5 or 2 µM) for 6, 12, 24, 36, 48 and 72 h. Vehicle control cells were treated with DMSO (0.1%). Cell number in each well was determined using the sulforhodamine B (SRB) assay (22).

Cell cycle analysis. Flow cytometry was used to analyze DNA content in order to determine cell cycle distribution. MDA-MB-231, MDA-MB-468 and SKBr3 cells were plated and treated with RL66 (1.5 or 2 µM) or 0.1% DMSO as control for 6-48 h in 6-well plates. The cells were harvested, washed with PBS and then fixed in 70% ethanol. Following rehydration with PBS, the cells were stained with PI in the dark at 4°C as described (23). The samples were analyzed via flow cytometry using Cell Quest Pro software. Results are expressed as percent of cells in each phase of the cell cycle.

Induction of apoptosis. MDA-MB-468, and SKBr3 cells were seeded in 6-well culture plate in 2 ml of DMEM/HamF12 supplemented with 5% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, 25 ng/ml amphotericin B and 2.2 g/l NaHCO₃. The cells were treated with RL66 (1.5 or 2 µM) or vehicle control for 12-36 h. Apoptosis was assessed using Annexin V-FLUCOS/PI staining, as described (24). The samples were analyzed using a FACSCalibur flow cytometer (BD Biosciences) and the proportion of apoptotic cells was determined using CellQuest Pro software.
various treatment groups. Mice were then orally gavaged with RL66 (0.85 or 8.5 mg/kg/day), or water as the vehicle control (5 ml/kg/day) for 10 weeks. Dosing solutions were prepared fresh each day.

Assessment of animal health. Food consumption and body weight were monitored daily throughout the treatment period. Mice were euthanized by CO$_2$ inhalation 24 h following the last dose and necropsies were then performed. Blood was collected via the inferior vena cava and placed on ice, while major organs, as well as tumors were excised and weighed. Organ weights are expressed as a percentage of body weight. Plasma was separated and used to determine hepatotoxicity via the plasma marker alanine aminotransferase (ALT) activity using a commercially available kit (Medica Pacifica, Auckland, New Zealand). Results are expressed as IU/l.

Immunohistochemistry of tumor sections. Tumors were embedded in OCT compound and then sectioned (12 mm), fixed in acetone, and air-dried overnight. Sections were then washed twice in Tween-20 PBS, incubated with normal serum for 30 min at room temperature, and then incubated overnight with primary CD105 antibody. Slides were then rinsed and peroxidase blocked using hydrogen peroxide (3%) before incubation with the appropriate secondary antibody for 30 min at room temperature in a humidified chamber. The sections were then incubated with ExtrAvidin (Bio-Rad Laboratories, Auckland, New Zealand) (1:20) for 30 min at room temperature in a humidified chamber before development with 3,3′-diaminobenzidine tetrahydrochloride as the chromogen and counterstaining with Mayer's haematoxylin. Once slides were dehydrated, DPX mounting medium and coverslips were applied. The sections were analyzed from tumors obtained from each mouse and a representative slide is shown in the results section.

Statistical analysis. All time course data were analyzed using a two-way ANOVA coupled with a Bonferroni post hoc test. Tumor volume was analyzed using a repeated measures 2-way ANOVA coupled with a Bonferroni post hoc test. For all data in which time was not a factor, the data were analyzed using a one-way ANOVA coupled with a Bonferroni post hoc test. p<0.05 was the minimum requirement for a statistically significant difference.

Results

Previously we have shown that RL66 elicited sub micromolar IC$_{50}$ values in three different ER-negative breast cancer cell lines (20). Therefore, the first aim of this study was to examine the time-course of RL66-mediated cytotoxicity toward MDA-MB-231, MDA-MB-468 and SKBr3 cells. The results showed that RL66 elicited time-dependent and cell line-dependent cytotoxicity (Fig. 2A-C). Specifically, time-dependent cytotoxicity was elicited in SKBr3 cells where 2 µM significantly increased cytotoxicity at 48 h compared with all previous time points (Fig. 2C). However, in the two TNBC cell lines no further cytotoxicity was elicited after 24 h. Thus, RL66 showed potent cytotoxicity toward SKBr3 cells compared to a cytostatic effect in TNBC cells.

We next examined whether the cytotoxicity of RL66 was due to cell cycle arrest. Treatment of MDA-MB-231,
MDA-MB-468, and SKBr3 cells with RL66 produced G2/M phase arrest in all three cell lines. Specifically, at 24 h, RL66 caused an 150% increase in the proportion of G2/M phase cells over control in both MDA-MB-231 (Fig. 3A) and MDA-MB-468 cells (Fig. 3B). In SKBr3 cells, after 6 and 12 h, the proportion of cells undergoing G2/M phase was increased by 130% and 120%, respectively, compared to control (Fig. 3C). Moreover, there was a significant reduction in the proportion of cells in S phase at 24 h. SKBr3 cells were also the only cell type to show an increase in subG1 cells.

To determine if RL66-mediated cell cycle arrest resulted in apoptosis, time-dependent changes in apoptosis were examined. The induction of apoptosis was time-dependent in SKBr3 cells, as 42% of cells were apoptotic after 36 h and this was significantly elevated compared to all other time points (Fig. 4B). In contrast, 15–22% of MDA-MB-468 cells underwent apoptosis and this effect was maintained from 12–36 h (Fig. 4A) indicating the lack of a time-dependent effect. G2/M arrest did not drive apoptosis in MDA-MB-468 cells, as apoptosis was increased at 12 h, which was prior to the increase in G2/M phase arrest. However, the early appearance of G2/M phase arrest at 6 h in SKBr3 cells is a likely reason why these cells show a strong apoptotic response over time. Our previous work with RL66 in MDA-MB-231 cells indicated that the induction of apoptosis was weakest in this cell line, as 18% of cells underwent apoptosis and this decreased to 8% after 18-36 h (20). Overall RL66 displayed a more potent cytotoxic effect in SKBr3 cells. To determine if this was due to the inhibition of HER2/neu expression, drug-mediated changes in HER2/neu and other downstream cell signaling proteins were determined via western blot analysis.

Treatment of SKBr3 cells with RL66 (2 μM) decreased the ratio of pHER2/HER2, with an almost complete inhibition for...
2-24 h (Fig. 5A). To link the changes in HER2/neu with cell cycle progression protein changes in the cyclin dependent kinase inhibitor, p27 were determined. The results showed that decrease in HER2/neu correlated with a significant increase in the expression of p27 at 12 and 36 h (Fig. 5B). Thus the decrease in HER2/neu leads to an increase in p27 leading to the observed G2/M arrest and apoptosis. The presence of apoptosis was also confirmed in SKBr3 cells by the significant increase in cleaved caspase-3 (Fig. 5C). Proteins downstream of EGFR were also examined and RL66 treatment resulted in a 90% decrease in the ratio of pAkt/Akt (Fig. 5D). This correlated with a decrease in mTOR and its downstream effector 4EBP1 (Fig. 5E and F). Conversely, the stress kinases JNK1/2 and p38 were transiently increased from 30 min-6 h (Fig. 5G and H). Thus, RL66 produces a consistent time-dependent disruption of cell signaling proteins in SKBr3 cells that begins with potent inhibition of HER2/neu.

To determine the molecular mechanisms responsible for apoptosis and cell cycle arrest in TNBC cells we first exam-
ined for other isoforms of the EGFR. RL66 failed to alter the ratio of pEGFR/EGFR protein levels (data not shown). However, RL66 did modulate the expression of Akt, mTOR, 4EBP1, NF-κB, JNK1/2, p38 and caspase-3 in MDA-MB-231 (Fig. 6) and Akt, mTOR, p27, JNK1/2, p38 and caspase-3 in MDA-MB-468 cells (Fig. 7). Specifically, RL66 significantly decreased the ratio of pAkt/Akt from 6-36 h in MDA-MB-231 cells and at 36 h in MDA-MB-468 cells (Figs. 6A and 7A). The stress initiated by the treatment of MDA-MB-231 and MDA-MB-468 cells resulted in a transient increase in both JNK1/2 and p38 MAPK phosphorylation (Figs. 6E, F and 7D, E). Furthermore, RL66 increased levels of cleaved caspase-3 at 12 and 24 h (Figs. 6G and 7F). MDA-MB-231 cells were the only cell line to show a significant decrease in NF-κB which occurred at 12-36 h (Fig. 6D).

To determine if RL66 could modulate angiogenesis, in vitro assays using HUVEC cells were performed, as the ability of these cells to migrate through matrigel and their ability to form tube-like networks are hallmarks of angiogenesis. Quantifiable and visual assays were used to form a more complete in vitro picture. The results showed that RL66 (1 µM) significantly reduced HUVEC cell migration by 46% compared to vehicle...
control (Fig. 8A) and completely inhibited endothelial tube formation (Fig. 8B).

To determine if these potent in vitro effects would translate to in vivo tumor suppression, RL66 was examined for its ability to modulate tumor growth in a xenograft model of TNBC. The results showed that tumors in mice treated with RL66 (8.5 mg/kg) were significantly smaller in volume compared to tumors from vehicle treated mice (Fig. 9A). This effect was apparent after 4 weeks of treatment and continued throughout the 10 weeks of treatment. At the conclusion of the study tumor volume and weight was 48% smaller in the RL66 treated mice compared to vehicle control mice. Importantly, RL66 treatment was non-toxic to the mice as body weight, gross organ weight of the liver, kidney, spleen and uterus was not different between treatment and control (data not shown). Additionally, plasma alanine aminotransferase activity, a marker of hepatotoxicity, remained in the normal range (23-85 IU/l). To determine if the tumor suppression elicited by RL66 was accompanied with a decrease in microvessel density, tumors were sectioned and stained for the blood vessel marker CD105. The results demonstrated that RL66 (8.5 mg/kg) significantly decreased CD105 staining 57% compared to control tumors (Fig. 9B and C).

Discussion

We have previously shown that RL66 elicited high cytotoxic potency towards ER-negative breast cancer cells (20). Therefore, this study was designed to further characterize this cytotoxic effect in vitro and in vivo. The results show that RL66 promoted G2/M cell cycle arrest, induced apoptosis and modulated the Akt-dependent signaling pathway and stress response MAPK pathway. RL66 also downregulated the expression of HER2/neu in SKBr3 cells. Importantly, RL66 suppressed tumor growth in vivo, while it remained non-toxic to major organs. In addition,
RL66 exhibited anti-angiogenic effects in vitro by inhibiting the invasion of HUVEC cells and their ability to form endothelial tube-like network and in vivo by decreasing microvessel density in tumor slices.

RL66 displayed potent cytotoxicity in ER-negative breast cancer cells compared to other cyclohexanone curcumin analogs (18,20). Moreover, it had superior cytotoxicity compared with other curcumin analogs such as 3,5-bis(flurobenzylidene) piperidin-4-one (EF24) (26), 5-bis(4-hydroxy-3-methoxybenzylidnen)-N-methyl-4-piperidone (PAC) (27) and GO-Y030 (28) in MDA-MB-231 cells. Specifically IC$_{50}$ values of 1.2, 1 and 0.3 µM were reported for EF24, GO-Y030 and RL66, respectively (20,26,28). While EF24 induced G2/M phase arrest and apoptosis in MDA-MB-231 cells (19) and inhibited the NF-κB pathway in a TNFα-dependent manner (26), it has not been examined in other breast cancer cells. Additionally, RL66 has a stronger ability to induce apoptosis compared to the analog 4-hydroxy-3-methoxybenzoic acid methyl ester (HM-BME), where 25 µM was required to cause 37% of LNCaP prostate cancer cells to undergo apoptosis after 24 h (29). The curcumin analogs FLLL11 and FLLL12 were equally potent as RL66 in MDA-MB-468 cells (19) and inhibited the NF-κB pathway in a TNFα-dependent manner (26), it has not been examined in other breast cancer cells. Additionally, RL66 has a stronger ability to induce apoptosis compared to the analog 4-hydroxy-3-methoxybenzoic acid methyl ester (HM-BME), where 25 µM was required to cause 37% of LNCaP prostate cancer cells to undergo apoptosis after 24 h (29). The curcumin analogs FLLL11 and FLLL12 were equally potent as RL66 in MDA-MB-468 cells (19) and inhibited the NF-κB pathway in a TNFα-dependent manner (26), it has not been examined in other breast cancer cells. Additionally, RL66 has a stronger ability to induce apoptosis compared to the analog 4-hydroxy-3-methoxybenzoic acid methyl ester (HM-BME), where 25 µM was required to cause 37% of LNCaP prostate cancer cells to undergo apoptosis after 24 h (29). The curcumin analogs FLLL11 and FLLL12 were equally potent as RL66 in MDA-MB-468 cells (19) and inhibited the NF-κB pathway in a TNFα-dependent manner (26), it has not been examined in other breast cancer cells. Additionally, RL66 has a stronger ability to induce apoptosis compared to the analog 4-hydroxy-3-methoxybenzoic acid methyl ester (HM-BME), where 25 µM was required to cause 37% of LNCaP prostate cancer cells to undergo apoptosis after 24 h (29). The curcumin analogs FLLL11 and FLLL12 were equally potent as RL66 in MDA-MB-468 cells with similar IC$_{50}$ values (0.3 µM). However, this did not translate to other breast cancer cell types as these analogs had IC$_{50}$s of 2-5 µM in MDA-MB-231 and SkBr3 cells (27). These analogs also downregulated Akt phosphorylation and HER2/neu expression in SkBr3 breast cancer cells but at concentrations of 10 µM, 5-fold greater than RL66 (30). Overall RL66 is more potent as all of its anticancer actions were elicited at concentrations of 3 µM or less.

Breast cancer patients whose tumors overexpress HER2/neu have a poor prognosis, shorter relapse time and lower survival time (31). In this study we showed that RL66 decreased HER2/neu expression in SkBr3 cells, which led to a decrease in Akt and mTOR as well as an increase in p27 and cleaved caspase-3. Since p27 is a key regulator of G2/M phase arrest and apoptosis (32,33), inhibition of HER2/neu is a key initial mechanism for the apoptotic effect elicited by RL66 in SkBr3 cells. RL66 was more potent than some curcumin analogs at down-regulating the expression of HER2/neu, as 4 µM concentrations of RL90 and RL91 and 10 µM concentrations of and FLLL11...
and FLLL12, were required to elicit a similar effect (30,34). However, it was not more effective than RL71, which inhibited HER2/neu at 1 µM (21). However, RL66 remains a strong drug candidate for ER-negative/HER2-positive breast cancer, especially since it has shown efficacy in vivo, which to date RL71 has not displayed (21)

MAPK signaling which includes activation of JNK and p38 is involved in the regulation of the cell cycle and induction of apoptosis in breast cancer cells (35). Various cytotoxic agents induce apoptotic cell death via activation of MAPK signaling and induction of caspase-3 (36-38). Our studies showed that RL66 treatment induced JNK1/2 and p38 MAPK in MDA-MB-231 and MDA-MB-468 cells. Anticancer agents such as curcumin, which causes activation of p38, JNK1/2 and caspase-3, also induce similar apoptotic events (39,40). The MAPK pathway may also upregulate the cell cycle regulatory protein, p27 in breast cancer cells (41). Our results demonstrated that in MDA-MB-468 RL66 enhanced the expression of p27 which would contribute to the observed G2/M cell cycle arrest.

We further studied the effect of RL66 on the PI3K/Akt/mTOR pathway. Akt is an important oncoprotein which is constitutively active in breast cancer cells and has been implicated in numerous regulatory mechanisms involving protein synthesis, cell cycle progression and inhibition of apoptosis (42,43). Our results showed that RL66 decreased the phosphorylation of Akt on Ser-473 in a cell line and time-dependent manner. Specifically, in MDA-MB-231 cells, RL66 decreased Akt phosphorylation after 6 h whereas in MDA-MB-468 cells the phosphorylation of Akt was only decreased after 36 h. However, RL66 was more potent than the analogs RL90 and RL91, which did not decrease the ratio of pAkt/Akt at concentrations of 4 µM (34). The decreased activity of Akt led to decreased activation of its substrate mTOR in both cell lines.

Akt contributes to the activity of NF-κB by controlling its translocation to the nucleus (44) and a decrease in Akt activity may affect the stability and level of NF-κB (45). NF-κB belongs to a family of transcription factors which has been associated with inhibition of apoptosis by promoting the expression of anti-apoptotic proteins such as Bcl-xL, c-Myb and caspase inhibitors (46,47). RL66 downregulated the expression of NF-κB in MDA-MB-231 cells. However, higher concentrations were required to downregulate NF-κB in MDA-MB-468 cells (data not shown) and this is consistent with other curcumin analogs (21,23). Curcumin has also been shown to interfere with the functions of Akt and MAPKs and to inhibit its downstream target NF-κB (48,49) and thus RL66 retains many of the same actions as curcumin.

Importantly, the potent in vitro actions of RL66 translated to tumor suppression in a xenograft model of TNBC. Tumor suppression was accompanied by a 57% decrease in tumor microvessel density. While other 2nd generation heterocyclic suppression was accompanied by a 57% decrease in tumor microvessel density. This anti-angiogenic effect was also shown in vitro. Thus, RL66 shows potential as a new drug therapy for ER-negative breast cancer that warrants further investigation.

Acknowledgements

This study was supported by a grant from the Breast Cancer Cure Research Trust (RJR) and a University of Otago postgraduate scholarship (BY).

References


